[HTML][HTML] Anticancer drug resistance: An update and perspective
R Nussinov, CJ Tsai, H Jang - Drug Resistance Updates, 2021 - Elsevier
Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
RAS-targeted therapies: is the undruggable drugged?
AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
Tumour extracellular vesicles and particles induce liver metabolic dysfunction
Cancer alters the function of multiple organs beyond those targeted by metastasis,. Here we
show that inflammation, fatty liver and dysregulated metabolism are hallmarks of …
show that inflammation, fatty liver and dysregulated metabolism are hallmarks of …
The frequency of Ras mutations in cancer
IA Prior, FE Hood, JL Hartley - Cancer research, 2020 - AACR
Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature
regarding the cancer mutation frequency of Ras, with quoted values varying from 10%–30 …
regarding the cancer mutation frequency of Ras, with quoted values varying from 10%–30 …
Emerging strategies to target RAS signaling in human cancer therapy
K Chen, Y Zhang, L Qian, P Wang - Journal of hematology & oncology, 2021 - Springer
Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
RAS isoforms and mutations in cancer at a glance
ABSTRACT RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP–GTP-
regulated binary on-off switches, which regulate cytoplasmic signaling networks that control …
regulated binary on-off switches, which regulate cytoplasmic signaling networks that control …
Therapeutic strategies to target RAS-mutant cancers
MB Ryan, RB Corcoran - Nature reviews Clinical oncology, 2018 - nature.com
RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …
A model for RAS mutation patterns in cancers: finding the sweet spot
S Li, A Balmain, CM Counter - Nature Reviews Cancer, 2018 - nature.com
The three RAS genes—HRAS, NRAS and KRAS—are collectively mutated in one-third of
human cancers, where they act as prototypic oncogenes. Interestingly, there are rather …
human cancers, where they act as prototypic oncogenes. Interestingly, there are rather …
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
MT Chang, S Asthana, SP Gao, BH Lee… - Nature …, 2016 - nature.com
Mutational hotspots indicate selective pressure across a population of tumor samples, but
their prevalence within and across cancer types is incompletely characterized. An approach …
their prevalence within and across cancer types is incompletely characterized. An approach …
A comparative analysis of individual RAS mutations in cancer biology
C Muñoz-Maldonado, Y Zimmer, M Medová - Frontiers in oncology, 2019 - frontiersin.org
In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode
four highly homologous proteins. RAS proteins are small GTPases involved in a broad …
four highly homologous proteins. RAS proteins are small GTPases involved in a broad …